GENyO

Name

GENyO

Legal name

FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL ALEJANDRO OTERO (FIBAO)

Website

https://genyo.es

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Genomics and Oncology Research Services

NAICS

Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

akta.pro secondary industries

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Genomic research services
• Oncology research
• Advanced therapy development
• Proteogenomic analysis
• Personalized medicine

Headquarters

HQ city

Granada

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: GENyO offers proteogenomic services, scientific consulting, equipment access, and specialized laboratory services to external pharmaceutical companies, healthcare providers, research institutions, and biotech companies seeking R&D capabilities in genomics and oncology.
2. Research Funding: The center receives funding from its founding partners (Pfizer, University of Granada, Junta de Andalucía), government research grants (Horizon 2020, European projects), and public research agencies (ISCIII, Plan Nacional, State Research Agency).
3. Spin-off Company Services: The center has created spin-off companies (LentiStem Biotech, CRISPNA Bio) based on generated patents and technologies, which may provide licensing revenue and commercialization pathways.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

GENyO is a joint genomics and oncology research center that provides proteogenomic analysis services, advanced therapy development (CAR-T and gene therapy), liquid biopsy diagnostics, and contract scientific research to pharmaceutical companies, hospitals, and research institutions. The center operates two main areas — Functional Genomics and Personalised Medicine — across 16 research groups with 207 personnel, supported by €80M-scale European project participation and 16 patents (6 licensed to spin-offs).

Product overview

GENyO is a biomedical research center (not a product company) offering proteogenomic and genomic services to external clients including patients with rare and common diseases and cancer. The center provides its services through the Unidad de Genómica y Bioinformática (Genomics and Bioinformatics Unit), which offers advanced proteogenomic analysis as its primary external-facing service. Research services include scientific consulting and equipment access. The center's work spans Functional Genomics and Personalized Medicine areas with strategic focus on the Human Genome, Cancer Genomics, Disease Detection/Diagnostics, and Advanced Therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Proteogenómica Service (Genomics and Bioinformatics Unit) Advanced proteogenomic analysis service that identifies and analyzes more than 1,000 proteins from a 4 µL sample, applying multi-omic integration for biomedical and translational research including disease studies, clinical cohorts, and limited samples. Used by external pharmaceutical companies, biotech firms, and research institutions.
• Advanced Therapy Development (ATMPs) Development of Advanced Therapy Medicinal Products including CAR-T cell therapies for cancer and gene therapy for Pompe disease, leveraging lentiviral vectors and CRISPR/Cas genome editing tools. Offered through research collaboration with pharmaceutical companies and clinical partners.
• Liquid Biopsy Services Liquid biopsy analysis service for cancer detection, diagnosis, monitoring and prognosis based on circulating cell-free DNA. Supports clinical decision-making for hospitals and serves as a translational research platform for pharma and biotech partners.
• Scientific Consulting and Equipment Access Scientific consulting and access to specialized genomics and proteomics equipment offered to external pharmaceutical companies, healthcare providers, and research institutions.

Quantifiable outcome

• >1000 proteins analyzed in 4 µL sample
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered minor, core and flagship.

• 22q11.2 Syndrome Association of AndalusiaminorStrategic or Co-development Partner · 1 January 2026Patient advocacy organization collaborating with GENyO and UGR researchers to promote comprehensive approach to 22q11.2 syndrome research and care.
• FIBAO (Fundación para la Investigación Biosanitaria de Andalucía Oriental Alejandro Otero)coreStrategic or Co-development Partner · 1 January 2024FIBAO is the foundation that manages and operates GENyO. It provides administrative, financial, and operational management services for the center. The foundation's Managing Director participates in the Governing Council.
• ibs.GRANADAcoreStrategic or Co-development Partner · 1 January 2024Instituto de Investigación Biosanitaria de Granada - collaborative research institute involving GENyO and other research institutions in Granada for joint biomedical research projects.
• Fundación Pública Progreso y SaludcoreStrategic or Co-development Partner · 1 January 2024Public foundation supporting biomedical research in Andalusia, collaborating with GENyO researchers on various projects including lupus research and other autoimmune diseases.
• NanoCARE 2.0 NetworkminorStrategic or Co-development Partner · 1 January 2024Thematic network of 15 multidisciplinary research groups focused on nanomedicine development for cancer, neurodegenerative diseases, and infectious diseases. GENyO's NanoChembio group participates, coordinated by Dr. Rosario Sánchez.
• LentiStem BiotechcoreStrategic or Co-development Partner · 1 January 2024Spin-off company founded by Dr. Francisco Martín based on licensed gene therapy patents. Focuses on development of lentiviral vector technologies for therapeutic applications.
• CRISPNA BiocoreStrategic or Co-development Partner · 1 January 2024Spin-off company founded by Dr. Francisco Martín based on CRISPR/Cas genome editing patents. Develops gene editing technologies for cancer and genetic disease therapies.
• CART_Andalucía ProjectcoreStrategic or Co-development Partner · 1 January 2024Regional CAR-T therapy development project moving into Phase 2 for CAR-T prototype development and preclinical studies, involving multiple Andalusian research institutions.
• Project LOLAminorStrategic or Co-development Partner · 1 January 2024Regional project promoting liquid biopsy technology implementation for improved cancer diagnosis and treatment across Andalusia.
• 3TR Project ConsortiumcoreStrategic or Co-development Partner · 1 January 2019Large-scale European research project with 80 million euro budget involving 9 international pharmaceutical companies. GENyO participates under Dr. Marta Alarcón's leadership, focusing on autoimmune diseases research.
• PRECISESADS ProjectminorStrategic or Co-development Partner · 1 January 2014Previous European collaborative project on autoimmune diseases that ran from 2014-2019, building foundation for subsequent 3TR project involvement.
• PfizerflagshipStrategic or Co-development Partner · 1 January 2010Pfizer is one of three founding partners of GENyO alongside the University of Granada and Junta de Andalucía. Pfizer contributes pharmaceutical industry expertise, funding, and access to drug development capabilities. The partnership enables translation of basic research into clinical applications.
• Universidad de Granada (UGR)flagshipStrategic or Co-development Partner · 1 January 2010The University of Granada provides academic research infrastructure, access to research talent including students and postdoctoral researchers, and integration with university departments. UGR's Vice-Chancellor serves as Chair of the GENyO Governing Council.
• Junta de AndalucíaflagshipStrategic or Co-development Partner · 1 January 2010The Regional Government of Andalusia provides governmental support, healthcare system integration, and regional funding. Representatives from various regional ministries participate in the GENyO Governing Council.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS): Barcelona biomedical research consortium linked to Hospital Clínic, with strong programs in genomics, oncology and advanced therapies. Comparable hospital-anchored translational model with EU project participation.
• Centre for Genomic Regulation (CRG): Barcelona-based institute focused on genomics, proteomics and computational biology. Closely comparable on genomics, multi-omic and bioinformatics capabilities, and on participation in EU consortia.
• Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's national cancer research center in Madrid, focused on oncology genomics and translational research. Directly comparable to GENyO's cancer genomics, advanced therapies and biomarker programs, with a similar mix of basic research and clinical translation.
• Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra: University-affiliated biomedical research center running programs in oncology, gene therapy and immunology. Comparable in advanced therapies, gene therapy and translational research orientation.
• Institute for Research in Biomedicine (IRB Barcelona): Public research center in Barcelona conducting multidisciplinary biomedical research with strong genomics, cell biology and disease-mechanism programs. Comparable in scope, public-private funding mix and research-group structure.
• Vall d'Hebron Institute of Oncology (VHIO): Oncology-focused translational research center embedded in a major Spanish hospital, running clinical trials and precision oncology programs. Highly comparable to GENyO's hospital-anchored, genomics-driven translational model.

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Intergovernmental European life-sciences research organization with broad genomics, structural biology and bioinformatics capabilities. Comparable on multi-omic integration and EU consortium participation, but at much larger scale.
• Broad Institute of MIT and Harvard: Major US genomics and biomedical research institute with leading programs in cancer genomics, CRISPR and single-cell biology. Comparable in advanced therapies and genomics, with much broader funding base and global reach.
• Wellcome Sanger Institute: UK-based genomic research institute with deep capabilities in sequencing, cancer genomics and large-scale consortia. Comparable in genomics focus and translational programs, but with substantially greater scale and funding.

Regional players

• IMDEA Nanociencia: Madrid-based regional research institute with strengths in nanotechnology and nanomedicine. Comparable as a Spanish public research center and partner in the NanoCARE 2.0 network alongside GENyO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/genyo_pts
• LinkedInlinkedin.com/company/pfizer-university-of-granada-junta-de-andalucia-center-for-genomics-and-oncological-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GENyO